PARTNER 3 Trial - Aortic Valve-in-Valve
This study is testing the safety and effectiveness of the Edwards SAPIEN 3/SAPIEN 3 Ultra transcatheter heart valve (THV). This device is used for people who have a failing artificial heart valve in their aorta (the body's main artery) that is causing severe aortic stenosis (a narrowing of the valve). You might be able to join if your existing artificial valve is failing, has a specific size, and you have certain heart symptoms (NYHA Functional Class ≥ II). Your heart care team must also agree that you are at low to intermediate risk. The study will measure success by looking at a combination of all-cause death and stroke one year after the procedure. The current status of this study is unclear, and it aims to enroll 125 participants.
- Study design
- This is a single-arm study, meaning all participants receive the same intervention. It aims to enroll 125 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for one year to assess all-cause mortality and stroke.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
PARTNER 3 Trial - Aortic Valve-in-Valve
At a glance
Conditions
Where it's being run
51 sites across 27 statesStudy leadership
- Chris S Malaisrie, MD · PRINCIPAL_INVESTIGATOR · Northwestern University
- Alan Zajarias, MD · PRINCIPAL_INVESTIGATOR · Washington University School of Medicine
- Mayra Guerrero, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and Effectiveness - Non-hierarchical composite of all-cause mortality and stroke1 year
Number of patients that died and/or had a stroke